The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | GCC19CART, a novel CAR T-cell therapy, shows promise in colorectal cancer
Bridget Keenan, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, highlights findings from a Phase I dose-escalation trial (NCT05319314) of GCC19CART, a chimeric antigen receptor (CAR) T-cell therapy targeting goblet cell carcinoma (GCC) in patients with refractory colorectal cancer, who have progressed after two or more lines of chemotherapy. At the higher dose level, high overall response rates were observed, with additional responses and stable disease observed at the lower dose level. Ongoing testing at the second dose level continues to show promising early signs of clinical efficacy. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
